| Literature DB >> 35912187 |
Ifra Mushtaq1, Gh Rasool Bhat1, Bilal Rah1, Syed Besina2, Sheikh Zahoor3, Muneer A Wani4, Mubashir A Shah4, Sadaf Bashir1, Muzamil Farooq1, Rafiq A Rather1, Dil Afroze1.
Abstract
Genetic instabilities exacerbated by the dysfunction of telomeres can lead to the development of cancer. Nearly 90% of all human malignancies are linked with telomere dysregulation and overexpression of telomerase, an enzyme that catalyzes the synthesis of telomeric DNA repeats at the ends of chromosomes. The burden of gastric cancer continues to inflict a deterring impact on the global health scenario, accounting for over one million new cases in 2020. The disease is asymptomatic in its early stages of progression, which is attributed to the poor prognosis and overall surge in mortality rate worldwide. Exploiting telomere physiology can provide extensive mechanistic insight into telomere-associated gastric cancer progression and its use as a target in a variety of therapeutic interventions. In this study, we aimed to evaluate the clinical implications of c-Myc, human telomerase reverse transcriptase (hTERT) expression, and telomere length in patients with gastric cancer. A total of 57 gastric cancer cases and adjacent controls were included in the study. RT-PCR and immunohistochemistry were used to assess the expression levels of c-Myc and hTERT. The relative telomere length was measured by MMQPCR using the Cawthon method. Our results indicated that the shorter telomere and increased hTERT expression were associated with gastric cancer progression. The study also highlighted the role of short telomeres and increased expression of hTERT in gastric cancer progression and its association with various etiological risk factors, transcriptional activators, and overall survival among the ethnic Kashmiri population of North India.Entities:
Keywords: North India; c-Myc; gastric cancer (GC); human telomerase reverse transcriptase (hTERT); telomeres
Year: 2022 PMID: 35912187 PMCID: PMC9326504 DOI: 10.3389/fonc.2022.919351
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
The various characteristic features of gastric cancer patients.
| Clinicopathological parameters | Controls | Cases | p-value |
|---|---|---|---|
|
| |||
| | 22 (55%) | 44 (77%) |
|
| | 18 (45%) | 13 (28%) | |
|
| |||
| | 30 (75%) | 41 (71.9%) | 0.37 |
| | 10 (25%) | 16 (28.07%) | |
|
| |||
| | 4 (10%) | 33 (57%) |
|
| | 36 (90%) | 24 (42.1%) | |
|
| |||
| | – | 23 (40.35%) | |
| | – | 20 (35.08%) | |
| | – | 7 (12.28%) | |
| | – | 7 (12.28%) | |
|
| |||
| | – | 5 (8.7%) | |
| | – | 19 (33.33%) | |
| | – | 33 (57.89%) | |
|
| |||
| | 32 (80%) | 50 (87.7%) | 0.27 |
| | 8 (20%) | 7 (12.28%) | |
|
| |||
| | 15 (37.5%) | 47 (82.45%) |
|
| | 25 (62.5%) | 10 (17.54%) | |
The bold values represents that they are statistically significant.
Figure 1Upregulation of c-Myc expression in gastric cancer. (A) Tissue. (B) Blood. (C) Stage III compared to stages I and II.
Association of c-Myc, hTERT expression, and relative telomere length with different clinicopathological findings in gastric cancer patients.
| Clinicopathological parameters | c-Myc expression | hTERT expression | Relative telomere length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Low expression | High expression | p-value | Low expression | High expression | p-value | Short telomeres | Long telomeres | p-value | |
|
| |||||||||
| | 08 | 33 |
| 12 | 29 |
| 32 | 10 |
|
| | 06 | 10 | 07 | 09 | 08 | 07 | |||
|
| |||||||||
| | 12 | 32 |
| 14 | 30 |
| 32 | 12 |
|
| | 01 | 12 | 5 | 8 | 08 | 05 | |||
|
| |||||||||
| | 07 | 26 |
| 10 | 23 |
| 26 | 07 |
|
| | 07 | 17 | 09 | 15 | 14 | 10 | |||
|
| |||||||||
| | 05 | 18 |
| 09 | 14 |
| 16 | 07 |
|
| | 06 | 14 | 07 | 13 | 13 | 07 | |||
| | 01 | 06 | 02 | 05 | 05 | 02 | |||
|
| 02 | 05 | 01 | 06 | 06 | 01 | |||
|
| |||||||||
| | 07 | 14 |
| 09 | 15 |
| 12 | 09 |
|
| | 07 | 29 | 10 | 23 | 28 | 08 | |||
The bold values represents that they are statistically significant.
Figure 2Increased expression of hTERT in gastric cancer. (A) Tissue. (B) Blood. (C) Late stage. and (D) Advanced age.
Figure 3(A) Representative images of immunohistochemistry (IHC) of c-Myc in (A) stage I, (B) stage II, and (C) stage III. (B) Representative images of immunohistochemistry (IHC) of hTERT in (A) stage I, (B) stage II, and (C) stage III.
Figure 4(A) Relative telomere length among cases and controls. (B) Advanced age. (C) Males compared to females. (D) Smokers compared to nonsmokers.
Figure 5The Kaplan–Meier survival plot depicts (A) overall survival (OS) in gastric cancer patients; (B) overall survival (OS) in different stages; (C, D) association of overall survival (OS) with c-Myc expression and hTERT expression; and (E) association of overall survival (OS) with relative telomere length.
Figure 6The heat map plot of hTERT and c-Myc expression. Columns of the plot represent the genes and the rows represent samples, respectively.
Figure 7Interaction of hTERT and c-Myc genes with other critical genes using various networks. Each color represents a different type of interaction and its role in various biological processes.
Figure 8Progression of gastric carcinoma is mediated by the binding of oncogene c-Myc to the hTERT promoter region via transcription factor domains MAD/MAX complex, resulting in upregulation of hTERT, which in turn causes the repeated synthesis of telomeric DNA and drives the cell toward tumorigenesis.